Identify Your Next High-Leverage Drug Target
AI-driven target identification and validation integrating multi-omics, genetic evidence, and functional genomics to de-risk drug discovery.
Key Evidence Sources
Our platform draws on the most comprehensive evidence sources in drug discovery - integrating genetic databases, multi-omics datasets, functional screening results and cross-species translatability data into a unified target confidence framework.
Targets with strong human genetic evidence have 2–3× higher clinical success rates. We ensure every candidate target is scored against GWAS, Mendelian Randomization, eQTL, rare variant and CRISPR functional data before prioritization.
Evidence We Integrate
Three Integrated Workstreams
AI-powered identification, genetic evidence integration and functional validation - delivering end-to-end target confidence.
Disease-Gene Network Analysis
- AI-powered knowledge graph traversal
- Multi-source evidence integration
- Causal pathway identification
- High-confidence target ranking
Literature & Patent Mining
- NLP-driven publication analysis
- Patent landscape mapping & FTO
- Competitive intelligence synthesis
- Emerging target trend detection
Druggability Scoring
- Structural binding site analysis
- Small molecule & biologic assessment
- Allosteric site identification
- RNA therapeutic evaluation
Mendelian Randomization
- Causal inference from GWAS data
- Instrument variable validation
- Bidirectional MR analysis
- Pleiotropy & sensitivity testing
Rare Variant & eQTL Analysis
- Burden test & collapsing analysis
- Expression QTL colocalization
- pQTL target prioritization
- Polygenic risk score integration
Clinical Phenotype Validation
- Patient phenotype-target matching
- EHR data integration
- Biomarker-driven indication selection
- Basket study opportunity analysis
Pathway & Downstream Analysis
- Pathway enrichment mapping
- Downstream effector identification
- Cross-pathway interaction analysis
- Therapeutic window estimation
In-Vitro & In-Vivo Validation
- CRISPR screen design & interpretation
- RNAi experimental support
- Disease model phenotype analysis
- Pharmacological probe studies
Cross-Species Translatability
- Ortholog expression analysis
- Model organism phenotype mapping
- Clinical relevance scoring
- Translational biomarker identification
From Evidence Mining to Target Dossier
Every stage driven by data, scored by AI and validated by biology.
Evidence Mining
GWAS, Open Targets, literature & patent databases
Multi-Omics Integration
Proteomics, transcriptomics, metabolomics
AI Prioritization
Network analysis & druggability scoring
Genetic Validation
MR, eQTL, rare variant analysis
Functional Validation
CRISPR, phenotype & pathway analysis
Target Dossier
Evidence synthesis & recommendation
Purpose-Built Platforms for Target Science
AI engines, genetic evidence pipelines and functional validation workflows - integrated into one target discovery platform.
A Target Discovery Partner Built Differently
AI-First Target Discovery
Knowledge graphs, transformer models and multi-omics integration are embedded in every analysis - not optional add-ons to manual curation.
Genetic Evidence at the Core
Every target is scored against GWAS, MR, eQTL and rare variant evidence. Genetic validation is not a secondary filter - it is the foundation.
Computational + Functional
We do not stop at in silico prioritization. CRISPR screens, pathway perturbation and disease model validation confirm biology before you commit.
Full Competitive Intelligence
Patent landscapes, competitor pipelines and clinical precedent analysis ensure your target has differentiation potential and freedom to operate.
Druggability Is Not Optional
Structural assessment, modality selection and allosteric site identification are built into prioritization - not discovered after target commitment.
Cross-Species Translatability
Ortholog analysis and model organism phenotype mapping ensure your target biology translates from bench to patient.
Ready to Identify Your Next Breakthrough Therapy?
Request a Target Assessment today and accelerate your discovery pipeline with high-confidence, de-risked targets.